Could have been worse22 Sep 2022 12:21
Agrred all a bit of a shambles really and you have to wonder why these queries haven't already been addressed.. However I was wondering this week if the share price action was indicative of ("a leak" ) the technology was going to be outright rejected... obviously some people did get wind of this news!!. After the initial shock of seeing the share price down and subsequently reading the RNS and also having access to the Stifel note I am starting to feel more positive than I did earlier this week. Yes bad news re the delays but positives outweigh this..my two takeaways are that the FDA are now fully engaged with Polarean / Linde rather than issuing another CRL next week, with all previous issues with the polarizer device having been resolved (positive news) and the FDA has no further issues here. So its now up to this leading German chemical company to meet regularly and sort this out in the next 90 days which they state they will.. I feel relatively confident that this will end well...
re: Linde & Nukem (this is in their June 2018 results... · identifying, evaluating and selecting a candidate, Linde who are one of the largest global industrial gas suppliers, and entering into agreements to package and distribute our proprietary 129Xe drug, in preparation for the Phase III clinical trials. We are fortunate to have Nukem Isotopes GmbH as a strategic investor and supplier of our enriched 129Xe raw material and we thank them for their support.